<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268604</url>
  </required_header>
  <id_info>
    <org_study_id>1180.2</org_study_id>
    <nct_id>NCT02268604</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers</brief_title>
  <official_title>Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 200 and 300 mg BIIB 722 CL Tablet Tid and 300 and 450 mg BIIB 722 CL Tablet Bid Over 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess safety, pharmacodynamics and pharmacokinetics of BIIB 722 CL
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma (AUC)</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum measured concentration of the analyte in plasma (tmax)</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total mean residence time of the analyte in the body (MRTtot)</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total clearance of the analyte in plasma (CLtot/f)</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of the analyte excreted in urine (Ae)</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose proportionality</measure>
    <time_frame>up to day 7</time_frame>
    <description>assessed by AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation factor</measure>
    <time_frame>up to day 7</time_frame>
    <description>(predose concentration/concentration after 8 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach steady state</measure>
    <time_frame>up to day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombocytic Na-H exchange (NHE-1) inhibition by AUC of pH recovery</measure>
    <time_frame>up to day 7</time_frame>
    <description>in vitro fluorescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in vital functions</measure>
    <time_frame>up to day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIIB 722 CL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB 722 CL</intervention_name>
    <arm_group_label>BIIB 722 CL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  18 to 55 years of age

          -  Broca index &gt;= -20% and &lt;= +20%

          -  Written informed consent according to Good Clinical Practice (GCP) and local
             legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  History or current gastrointestinal hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

          -  Use of any drugs, which might influence the results of the trial within 10 days prior
             to administration or during the trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration of during trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the clinically accepted reference range
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

